| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/22/2007 | CA2619480A1 Method of using potassium channel inhibiting compounds |
| 02/22/2007 | CA2619462A1 Phosphodiesterase 10 inhibitors |
| 02/22/2007 | CA2619459A1 Novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
| 02/22/2007 | CA2619386A1 Method of reducing the risk of adverse cardiovascular (cv) events associated with the administration of pharmaceutical agents which favor cv events |
| 02/22/2007 | CA2619276A1 Pentacyclic kinase inhibitors |
| 02/22/2007 | CA2619262A1 Pyrazolone derivatives for the treatment of tuberculosis |
| 02/22/2007 | CA2619249A1 Benzoquinazoline derivatives and their use in treating bone disorders |
| 02/22/2007 | CA2619228A1 Pyrazole derivatives as therapeutic agents |
| 02/22/2007 | CA2619223A1 Fluoro substituted 2-oxo azepan derivatives |
| 02/22/2007 | CA2619219A1 Use of .beta.-1,3 (4)-endoglucanohydrolase, .beta.-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
| 02/22/2007 | CA2619217A1 Neurorestoration with r(+) pramipexole |
| 02/22/2007 | CA2619145A1 Use of choline to prevent thrombosis associated with total parenteral nutrition |
| 02/22/2007 | CA2619049A1 Compounds and compositions as protein kinase inhibitors |
| 02/22/2007 | CA2619040A1 Crystalline and amorphous sodium atorvastatin |
| 02/22/2007 | CA2619039A1 1-acyldihydropyrazole derivatives |
| 02/22/2007 | CA2619010A1 Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/22/2007 | CA2619005A1 Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| 02/22/2007 | CA2618988A1 Methods of making radiolabeled tracers and precursors thereof |
| 02/22/2007 | CA2618895A1 Methods and compositions for soothing oral and nasal tissues |
| 02/22/2007 | CA2618871A1 Ophthalmic compositions containing mucoadhesive polysaccharides able to promote corneal re-epithelization |
| 02/22/2007 | CA2618844A1 Monocyclic and bicyclic compounds and methods of use |
| 02/22/2007 | CA2618834A1 Selected cgrp antagonists, methods for the production thereof and their use as medicaments |
| 02/22/2007 | CA2618747A1 Substituted imidazole compounds as ksp inhibitors |
| 02/22/2007 | CA2618724A1 Imidazole compounds that modulate hsp90 activity |
| 02/22/2007 | CA2618723A1 Bis(thio-hydrazide amide) formulation |
| 02/22/2007 | CA2618713A1 Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
| 02/22/2007 | CA2618702A1 Sustained release antihistamine and decongestant composition |
| 02/22/2007 | CA2618679A1 Compounds for the treatment of inflammatory disorders |
| 02/22/2007 | CA2618653A1 Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder |
| 02/22/2007 | CA2618641A1 Cyclopropyl compounds and compositions for delivering active agents |
| 02/22/2007 | CA2618638A1 Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas |
| 02/22/2007 | CA2618634A1 Compounds and compositions as tpo mimetics |
| 02/22/2007 | CA2618614A1 Heterobicyclic compounds useful as p38 kinase inhibiting agents |
| 02/22/2007 | CA2618613A1 Protein kinase modulation by hops and acacia products |
| 02/22/2007 | CA2618568A1 Thiazolyl piperidine derivatives useful as h3 receptor modulators |
| 02/22/2007 | CA2618566A1 Non-nucleoside reverse transcriptase inhibitors |
| 02/22/2007 | CA2618560A1 Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection |
| 02/22/2007 | CA2618550A1 Indole derivatives as crth2 receptor antagonists |
| 02/22/2007 | CA2618516A1 New crystalline form of perindopril erbumine |
| 02/22/2007 | CA2618513A1 Unsaturated heterocyclic derivatives |
| 02/22/2007 | CA2618451A1 Amide derivatives |
| 02/22/2007 | CA2618448A1 Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents |
| 02/22/2007 | CA2618377A1 Pyrazole compounds that modulate hsp90 activity |
| 02/22/2007 | CA2618340A1 Piperidine and piperazine derivatives as p2x3 antagonists |
| 02/22/2007 | CA2618335A1 Antiviral phosphoramidates of 4'-substituted pronucleotides |
| 02/22/2007 | CA2618212A1 Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same |
| 02/22/2007 | CA2618110A1 Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics |
| 02/22/2007 | CA2618057A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 02/22/2007 | CA2618018A1 A concentrated liquid formulation comprising a s1p receptor agonist |
| 02/22/2007 | CA2617979A1 Combination of a pyrimydlaminobenzamide tyrosine kinase inhibitor and a histone deacetylase inhibitor |
| 02/22/2007 | CA2617963A1 Oil-in-water-type emulsion for topical application in dermatology |
| 02/22/2007 | CA2617958A1 Peg-ifn alpha and ribavirin for hbv treatment |
| 02/22/2007 | CA2617828A1 Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation methodthereof and use of same in |
| 02/22/2007 | CA2617642A1 Treatment of proliferative disorders |
| 02/22/2007 | CA2617636A1 Use of histone deacetylase inhibitors for treating cardiac hypertrophy and heart failure |
| 02/22/2007 | CA2617623A1 Combination methods of saha and targretin for treating cancer |
| 02/22/2007 | CA2617372A1 Substituted indoles and use thereof |
| 02/22/2007 | CA2617367A1 Solid dosage forms of valsartan and amlodipine and method of making the same |
| 02/22/2007 | CA2617359A1 Compounds and compositions as protein kinase inhibitors |
| 02/22/2007 | CA2617346A1 Piperazine derivatives |
| 02/22/2007 | CA2617107A1 Olanzapine analogs and methods of use thereof |
| 02/22/2007 | CA2617106A1 Estrogen compositions and therapeutic methods of use thereof |
| 02/22/2007 | CA2616318A1 Acetylenic piperazines as metabotropic glutamate receptor antagonists |
| 02/22/2007 | CA2616308A1 Bicyclic piperazines as metabotropic glutamate receptor antagonists |
| 02/22/2007 | CA2616307A1 Substituted piperazines as metabotropic glutamate receptor antagonists |
| 02/22/2007 | CA2615121A1 Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion |
| 02/22/2007 | CA2614864A1 The ocean wave energy converter (owec) |
| 02/22/2007 | CA2613465A1 Crystalline forms fenoldopam mesylate |
| 02/22/2007 | CA2608245A1 Process for the preparation of losartan potassium |
| 02/21/2007 | EP1754718A2 Inactivation resistant factor VIII |
| 02/21/2007 | EP1754712A2 Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| 02/21/2007 | EP1754710A2 2'-Fluoroncucleosides |
| 02/21/2007 | EP1754707A2 Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes |
| 02/21/2007 | EP1754706A1 SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON |
| 02/21/2007 | EP1754705A2 Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders |
| 02/21/2007 | EP1754703A2 N-Heterocyclic derivatives as nos inhibitors |
| 02/21/2007 | EP1754702A1 Epigallocatechin dimers or trimers having lipase inhibitory activity and/or antioxidative activity |
| 02/21/2007 | EP1754492A1 Novel drug discovery target and medicine acting on the same |
| 02/21/2007 | EP1754491A1 Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
| 02/21/2007 | EP1754484A1 Condensed pyrimidine derivatives as inhibitors of foic acid-dependent enzymes |
| 02/21/2007 | EP1754483A1 Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them |
| 02/21/2007 | EP1754482A1 Use of an ascomycin for the treatment of blepharitis |
| 02/21/2007 | EP1754481A2 Use of antifungal agents for treating otitis externa |
| 02/21/2007 | EP1754480A2 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 02/21/2007 | EP1754479A1 Capsule stable against mastication |
| 02/21/2007 | EP1754478A1 Solid Composition comprising a NO donor and a Dithiolane and its use for improvement of sexual function |
| 02/21/2007 | EP1754477A2 Hydroxamic acid derivatives as antibacterials |
| 02/21/2007 | EP1754476A1 Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| 02/21/2007 | EP1754475A1 Use of C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 02/21/2007 | EP1754474A1 Use of S-Clenbuterol |
| 02/21/2007 | EP1754473A1 Antitumor agent |
| 02/21/2007 | EP1754472A2 Compositions for treatment of disorders associated with chlamydia |
| 02/21/2007 | EP1754469A1 Injectable suspensions having improved injectability properties |
| 02/21/2007 | EP1753997A1 Photochromic material comprising a proteorhodopsin apoprotein and retinal analog |
| 02/21/2007 | EP1753858A2 Novel saccharothrix strain and antibiotics derived therefrom, i.e. mutactimycins and aldgamycins |
| 02/21/2007 | EP1753852A1 Compositions with health and nutrition promoting characteristics, containing interestified lipids and phytosterol, and related methods |
| 02/21/2007 | EP1753803A2 Polypeptides with the capacity to entrap drugs and release them in a controlled way |
| 02/21/2007 | EP1753775A1 Process for preparing acyclic hcv protease inhibitors |
| 02/21/2007 | EP1753767A1 Bicyclic heterocycles as hiv integrase inhibitors |
| 02/21/2007 | EP1753766A1 Tetraazabenzo(e)azulene derivatives and analogs thereof |